Head-to-head evidence
BCD-264 vs SAR442085
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
BCD-264
Marketed by Biocad
Phase 3 in Multiple Myelomamonoclonal antibody (biosimilar)
not yet graded
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
SAR442085
Developed by Sanofi
Phase 1 in Multiple Myelomabiologic
Weak signal
NCT04000282 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCD-264's landscape · SAR442085's landscape